ClinicalTrials.gg
RecruitingNCT07629154Updated Jun 15, 2026

Smart Discharges for Older Children

An observational study in Sepsis, sponsored by University of British Columbia. Recruiting at 7 sites in 5 countries. Open to participants aged 5 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by University of British Columbia · Observational

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
4,000
Ages
5 Years to 16 Years
Sex
All
01

Study summary

This study is an observational multi-country cohort study that aims to build algorithms that can identify children between 5 and 16 years of age admitted for proven or suspected sepsis who are at risk of mortality after they are discharged in East Africa.

In low- and middle-income countries, about 5% of children discharged after hospitalization for sepsis will die in the weeks after returning home. Doctors and parents are often unaware of this period of vulnerability and are poorly equipped to identify or handle this critical situation. This project builds on past work that developed and evaluated models and the Smart Discharges program to predict, during hospitalization, an individual child's risk of recurrent illness and mortality, as well as to provide additional post-discharge support to at-risk children.

Participants will be enrolled from facilities once they are admitted, collecting clinical and social variables. They will then be followed until 6 months post-discharge to understand what happens to them after they return home. This data will be evaluated to identify which variables collected at facilities can be predictive of mortality and recurrent illness after discharge.

Read the detailed description

PURPOSE The purpose of our research is to develop and expand the Smart Discharges approach to improve outcomes among all pediatric populations, and ultimately to build a scalable solution for improving post-discharge outcomes.

HYPOTHESIS Post-discharge mortality can be predicted, using admission variables, for children under 16 years of age who are admitted with suspected sepsis. Furthermore, a high proportion of these children will experience long-term reductions in health-related quality of life over the post-discharge period.

JUSTIFICATION With an improved understanding of risk, and an ability to determine risk at the bedside among older children, the existing Smart Discharge program can be expanded to be more inclusive, applicable to all pediatric patients with suspected sepsis, further simplifying implementation initiatives. This also further increases optimization of resource allocation within the health system. Such programs in precision public health can not only save lives and resources, but are much more likely to be scalable in economically strained environments

OBJECTIVES

The study aims to:

  1. Develop and internally validate a clinical risk prediction model for identifying children 5-\<16 years of age admitted for proven or suspected sepsis who are at high-risk of post-discharge death
  2. Quantitatively evaluate health-related quality of life (HRQL) and functional status up to 12 months post-discharge in children 5-\<16 years of age admitted for proven or suspected sepsis.
  3. Qualitatively assess post-discharge experiences of children 5-\<16 years of age admitted for proven or suspected sepsis, and the experiences of their families and health workers providing care.

RESEARCH DESIGN This is a mixed-methods study at a regionally representative sample of public hospitals providing pediatric care in East Africa. There will be three phases to this study, each corresponding to a specific objective.

Phase I - Model Derivation and internal validation: The investigators will conduct an observational cohort study in 4000 children 5-16 years of age informed through direct observation of the child prior to facility discharge and through telephone follow-up visits at 2-, 4-, and 6-months post-discharge. The objective of this study is to i) build a model to predict post-discharge mortality within 6 months of discharge among children 5-16 years of age.

Phase II - HRQL \& Functional Status Evaluation: The investigators will conduct an observational cohort study in a random subset of 500 children aged 5 - \<16 years enrolled in phase I. Using survey-based methodology, the investigators will conduct face-to-face caregiver interviews at admission, and telephone interviews will be conducted 2-,4-, 6-, and 12-months post-discharge. The objective of this study is to determine the HRQL and Functional Status Score (FSS) trajectory of sepsis during the first 6 months following discharge.

Phase IIIa: The investigators will conduct a qualitative study using focus group discussions with caregivers and community health workers. The objective of this study is to better understand the experiences of patients and caregivers during the post-discharge period, as well as the barriers and facilitators to effective care seeking during the post-discharge period.

Phase IIIb: The investigators will conduct a qualitative study using key informant interviews with health workers. The objective of this study is to better understand the perspective of health workers' discharge decision-making as well as caregiver interactions with the health system during the discharge and post-discharge period.

STATISTICAL ANALYSIS PLAN Phase I Our initial analysis will examine age- and sex-based interactions to identify an optimal set of key variables for modelling. This approach allows us to account for multiple factors that may contribute to age or sex based differences in vulnerability. With our sample size the study is powered to include age/sex as individual and interactive predictors. The study is not powered to build models within segregated age/sex groups, as this is not our intended output. Derivation of prediction models will be based on optimization of the Area Under the Receiver Operating Characteristic (AUROC) and specificity across a variety of modeling and variable selection approaches (e.g. logistic regression, elastic net, support vector machines). Model performance will be based on appropriate resampling techniques for internal validation (e.g., cross-validation, bootstrapping). The study will focus on developing parsimonious predictive models (e.g., 5-10 predictor variables) with high sensitivity (>80%) to reduce false negatives and maximize model use in resource-limited settings. AUROC, sensitivity, and specificity will be reported for each model, along with positive and negative predictive values. The investigators will compare country-specific metrics to ensure consistency across settings, and consider country-specific recalibration if model performance is lower than expected (>5% drop). The investigators will also summarize all risk factors for children who do and do not experience poor outcomes and estimate univariate associations. Outcomes and risk factors will be reported by sex and age category.

Phase II The investigators will use one-way Analysis if Variance (ANOVA) to test for significant difference in mean scores across groups of interest (e.g., sex, nutritional status, study site), and post-hoc Tukey HSD (Honest Significance Difference) test to perform pair-comparison in mean scores between different groups. They will also conduct descriptive statistical analysis with survival curves stratified by groups of interest for outcome event, and a mixed effects model, which can be used to model the longitudinal change in the outcome scores. The investigators will use univariable and multivariable logistic regression modeling to perform exploratory analysis examining associations between markers of critical illness (e.g., vital signs and clinical signs and symptoms collected in Aim 1) and our primary outcome for this Aim (persistent deterioration of HRQL). Odds ratios with 95% confidence intervals will be reported for all risk factors. Descriptive themes include barriers to care and post-discharge health-seeking behavior, while interpretive themes focus on caregiver and health worker perceptions of child death and disability, quality of life post-discharge, and the role of the health system in maintaining health. The investigators will employ member checking with a sample of participants to ensure validity of our results.

Phase III A team of researchers and clinicians from each of our study sites will lead data analysis. They will analyze focus group discussions using a framework method, which allows themes to be developed inductively from participants and deductively from existing literature. Through an iterative process, transcripts will be coded and analyzed for descriptive and interpretive themes using NVivo 12. Codes will be grouped and organized to summarize common themes from participants' lived experiences. Descriptive themes include barriers to care and post-discharge health-seeking behavior, while interpretive themes focus on caregiver and health worker perceptions of child death and disability, quality of life post-discharge, and the role of the health system in maintaining health. The team of researchers will employ member checking with a sample of participants to ensure validity of our results.

02

Conditions studied

  • Sepsis

Browse trials for

Keywords

  • pediatrics
  • sepsis
  • risk-prediction
  • critical care
  • post-discharge
  • patient discharge
03

In context

Sepsis

2,416 studies on the registry are indexed under Sepsis; 541 are open to participants now.

This study's planned enrollment of 4,000 is above the median of 150 across 1,162 observational studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

University of British Columbia is the lead sponsor of 1,339 studies on the registry; 259 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population is children admitted to hospital facilities with suspected or proven sepsis between 5-16 years of age in the catchment area of the 8 study sites: Mbarara Regional Referral Hospital (Uganda), Jinja Regional Referral Hospital (Uganda), Uganda Martyrs Ibanda Hospital (Uganda), Holy Innocents Children's Hospital (Uganda), Sekou-Toure Regional Referral Hospital (Tanzania), Bugando Medical Centre (Tanzania), Masaka Hospital (Rwanda), University Teaching Hospital of Kigali (Rwanda), Ruhengeri Referral Hospital (Rwanda).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 0 and 16 years admitted to pediatric ward of hospital for proven or suspected infection
  • Provide
  • Ability to provide contact information (phone number or address) for phone or in-person follow-up

Exclusion criteria

Exclusion Criteria:

  • Child lives outside of the catchment area of a study site
  • Admitted for elective procedures, trauma, or short-term observation
  • Language barriers
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
4,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pediatric patients 5-16 years of age

    Pediatric patients admitted to a study site with suspected or proven infection

    Other: No Intervention: Observational Cohort

Interventions

  • OtherNo Intervention: Observational Cohort

    This is a non-interventional study

06

What researchers measure

Primary outcomes

  1. Number of children who die post-discharge

    Time frame: Discharge until 6 months post-discharge

Secondary outcomes

  1. Number of children readmitted to a health facility post-discharge

    Time frame: Discharge until 6 months post-discharge

07

Study locations

2 of 7 sites recruiting
  • University of California, San Francisco
    San Francisco, California 94117, United States
    Not yet recruiting
    • Anneka Hooft, MD, MPH · Sub investigator
    • Teresa Kortz, MD, MS, PhD · Sub investigator
    • Charles Langelier, MD, PhD · Sub investigator
  • Weill Cornell Medicine
    Ithaca, New York 14850, United States
    Not yet recruiting
    • Duncan Hau, MD · Sub investigator
    • Radhika Lu Sundararajan, MD, MA, PhD · Sub investigator
  • University of Washington
    Seattle, Washington 98195, United States
    Not yet recruiting
    • Jerry Zimmerman, MD, PhD · Sub investigator
  • BC Children's Hospital Research Institute
    Vancouver, British Columbia V5Z 2X8, Canada
    Active, not recruiting

    Not enrolling at this site.

  • The Rwanda Paediatric Association
    Kigali, Rwanda
    Recruiting
    • Christian Umuhoza, MD · Principal investigator
    • Emmanuel Uwiragiye · Sub investigator
  • Catholic University Of Health And Allied Sciences
    Mwanza, Tanzania
    Recruiting
    • Neema Kayange, MD · Principal investigator
    • Rob Peck · Sub investigator
    • Bahati Msaki · Sub investigator
    • Stephen Mshana, MD, MMed, PhD · Sub investigator
  • WALIMU
    Mbarara, Uganda
    Completed

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: Yes — After the study period, a de-identified copy of the data will be prepared for deposition in a repository with open access with proper governance mechanisms. The investigators will make every effort to prevent re-identification of subjects by coding data that has the potential of being identifiable. For example, they will convert all dates into meaningful decimal numbers (date of birth into days since birth and date of recruitment will be reduced to month of recruitment) and all locations will be coded into data that is useful but not specific (such as address converted to distance and direction from facility). The investigators will ensure that data elements with small numbers of subjects (less than 10) will be coded or lumped to avoid identification. The de-identified study data will be made available using a data hosting service (e.g., Dataverse, Vivli, etc.)

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be deposited to an open access repository with moderated access within 2 years of study completion

Access criteria: Moderated access on a case-by-case basis.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Apr 2027, 39 months after the start.

Of 491 non-industry observational studies under Sepsis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 58. This study's planned 39 months is above that.

Counting every sponsor, half of 543 studies reached it within 27 months; a quarter within 12 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jun 5, 2026
StartActual
Jan 2, 2024
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07629154
Collaborators
University of California, San Francisco, World Alliance for Lung and Intensive Care Medicine in Uganda, Catholic University of Health and Allied Sciences, Centre Hospitalier Universitaire de Kigali
Responsible party
Matthew Wiens (Assistant Professor, University of British Columbia) — Principal investigator
First posted
Jun 5, 2026
Start date
Jan 2, 2024
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Jun 15, 2026

Study contacts

Matthew Wiens, PhD
Contact
matthew.wiens@bcchr.ca
604-829-2562

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion